908 Devices (MASS) Competitors

908 Devices (NASDAQ:MASS) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.

Which has more volatility and risk, MASS or CTKB?

908 Devices has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Which has stronger earnings and valuation, MASS or CTKB?

Cytek Biosciences has higher revenue and earnings than 908 Devices. Cytek Biosciences is trading at a lower price-to-earnings ratio than 908 Devices, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$59.63M	3.16	-$36.40M	-$2.10	-2.54
Cytek Biosciences	$200.45M	2.37	-$12.15M	-$0.05	-74.10

Does the media favor MASS or CTKB?

In the previous week, 908 Devices had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 7 mentions for 908 Devices and 6 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.85 beat 908 Devices' score of 0.54 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate MASS or CTKB?

908 Devices currently has a consensus target price of $5.33, indicating a potential upside of 0.06%. Cytek Biosciences has a consensus target price of $6.42, indicating a potential upside of 73.19%. Given Cytek Biosciences' higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cytek Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the MarketBeat Community prefer MASS or CTKB?

Cytek Biosciences received 3 more outperform votes than 908 Devices when rated by MarketBeat users. However, 48.72% of users gave 908 Devices an outperform vote while only 45.83% of users gave Cytek Biosciences an outperform vote.

Company	Underperform	Outperform
908 Devices	Outperform Votes 19 48.72%	Underperform Votes 20 51.28%
Cytek Biosciences	Outperform Votes 22 45.83%	Underperform Votes 26 54.17%

Do institutionals and insiders hold more shares of MASS or CTKB?

88.1% of 908 Devices shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 27.7% of 908 Devices shares are held by company insiders. Comparatively, 9.6% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is MASS or CTKB more profitable?

Cytek Biosciences has a net margin of -5.05% compared to 908 Devices' net margin of -109.11%. Cytek Biosciences' return on equity of -2.58% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-109.11%	-24.60%	-19.23%
Cytek Biosciences	-5.05%	-2.58%	-2.05%

Summary

Cytek Biosciences beats 908 Devices on 10 of the 17 factors compared between the two stocks.